Graves` Disease (Overactive Thyroid)

Global Graves` Disease (Overactive Thyroid) Market to Reach US$487.1 Million by 2030

The global market for Graves` Disease (Overactive Thyroid) estimated at US$397.9 Million in the year 2024, is expected to reach US$487.1 Million by 2030, growing at a CAGR of 3.4% over the analysis period 2024-2030. Anti-thyroid Drugs, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$209.7 Million by the end of the analysis period. Growth in the Beta Blockers segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$108.4 Million While China is Forecast to Grow at 6.4% CAGR

The Graves` Disease (Overactive Thyroid) market in the U.S. is estimated at US$108.4 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$97.1 Million by the year 2030 trailing a CAGR of 6.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Graves` Disease (Overactive Thyroid) Market – Key Trends & Drivers Summarized

Why Is Graves` Disease Emerging as a Global Public Health Concern?

Graves` disease, the leading cause of hyperthyroidism worldwide, is gaining increasing attention from health systems due to its rising prevalence, underdiagnosis, and its significant impact on metabolic health. This autoimmune disorder, characterized by excessive thyroid hormone production due to thyroid-stimulating immunoglobulins (TSIs), disproportionately affects women and often manifests in individuals aged 30 to 50. Although treatable, if left unmanaged, it can lead to serious complications, including cardiovascular stress, osteoporosis, eye disease (Graves` orbitopathy), and fertility issues.

The global increase in autoimmune diseases, driven by genetic susceptibility, environmental triggers, and lifestyle changes, has pushed Graves` disease further into the spotlight. A heightened awareness of thyroid-related disorders, especially in women’s health, and routine thyroid function testing have also contributed to higher detection rates. Public health agencies are increasingly including thyroid health in their preventive care programs, particularly in North America, Europe, and parts of Asia where autoimmune thyroid conditions are more prevalent.

How Are Diagnostics and Treatment Modalities Evolving to Improve Disease Management?

The diagnostic landscape for Graves` disease has significantly improved, driven by the widespread availability of thyroid-stimulating hormone (TSH) assays, radioactive iodine uptake tests, and anti-thyroid antibody profiling. Innovations in imaging technology, such as high-resolution thyroid ultrasound and radionuclide scanning, now allow for more accurate disease staging and differentiation from other forms of hyperthyroidism. This has enabled clinicians to make timely and precise treatment decisions, especially in cases where thyroid nodules or coexisting autoimmune conditions complicate the clinical picture.

Treatment approaches for Graves` disease continue to evolve along three primary paths: antithyroid medications (like methimazole and propylthiouracil), radioactive iodine therapy (RAI), and thyroidectomy. Each option is selected based on patient-specific factors including age, disease severity, pregnancy status, and comorbidities. Recent studies have focused on improving the long-term safety and tolerability of antithyroid drugs, particularly regarding hepatotoxicity and agranulocytosis risks. In parallel, advancements in minimally invasive thyroid surgeries and targeted radioiodine dosing have reduced complications and improved post-treatment quality of life. Novel therapies under investigation include biologics targeting TSH receptor antibodies and immune modulators aimed at altering the disease course rather than just controlling symptoms.

Which Regions and Patient Demographics Are Shaping Market Demand?

Graves` disease exhibits varying prevalence and management patterns across regions. North America leads the market in terms of diagnosis and treatment accessibility, supported by high healthcare expenditure, established endocrinology networks, and public awareness campaigns. Europe follows closely, where countries like the UK and Germany have robust screening programs and comprehensive autoimmune disease management frameworks. In the Asia-Pacific region, rising healthcare infrastructure and increasing urban awareness are contributing to improved diagnosis rates, although large rural populations still face underdiagnosis and limited access to endocrine specialists.

Demographically, women account for over 75% of all diagnosed cases of Graves’ disease, particularly during reproductive years, prompting focused efforts in women`s health screening and research. The condition is also increasingly observed in adolescents and perimenopausal women, creating additional layers of diagnostic and therapeutic complexity. Furthermore, the demand for long-term monitoring and ophthalmologic support in cases of thyroid eye disease is creating secondary markets for supportive diagnostics and surgical interventions in specialty care.

The Growth in the Graves’ Disease Market Is Driven by Several Factors…

The growth in the Graves’ disease market is driven by several factors directly tied to evolving treatment protocols, diagnostic innovation, and expanding access to endocrinological care. Technologically, the development of more sensitive immunoassays, refined imaging tools, and companion diagnostic kits has significantly improved disease detection and monitoring capabilities. These advancements enable personalized treatment strategies that minimize risks and enhance long-term outcomes.

On the end-use front, the increasing burden of autoimmune thyroid diseases, along with heightened public awareness and routine screening practices, is expanding the treatment population. The emergence of integrated thyroid care models—combining endocrinology, ophthalmology, and surgical expertise—is further boosting demand for advanced care services. Additionally, rising healthcare expenditure in emerging economies and the growth of tele-endocrinology platforms are improving access to care in previously underserved regions. With ongoing clinical trials focused on immunotherapies and disease-modifying drugs, the therapeutic landscape is poised for innovation, signaling continued expansion of the Graves’ disease treatment market globally.

SCOPE OF STUDY:

The report analyzes the Graves` Disease (Overactive Thyroid) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Treatment (Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy, Other Treatments); Administration Route (Oral, Parenteral, Other Administration Routes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

• Abbott Laboratories
• Apitope International NV
• bioMérieux SA
• Crinetics Pharmaceuticals
• F. Hoffmann-La Roche Ltd
• HanAll Biopharma
• Horizon Therapeutics (Amgen Inc.)
• Immunovant, Inc.
• Institute of Isotopes Co., Ltd.
• Jubilant Pharma Holdings Inc.
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Sanofi
• Sling Therapeutics
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Thermo Fisher Scientific Inc.
• Tourmaline Bio
• Viridian Therapeutics

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.